Spots Global Cancer Trial Database for Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer
Official Title: Concomitant Tarceva® and Irradiation in Patients in Local-regionally Advanced Non-small Cell Lung Cancer. A Phase II Study
Study ID: NCT00888511
Conditions
Study Description
Brief Summary: The trial is a phase II study of daily Tarceva combined with definitive radiotherapy in inoperable locally advanced non small cell lung cancer (stage IIB-IIIB). The objective of the phase II trial is to examine Tarceva concomitant with curatively intended irradiation 66 Gy (2 Gy x 33 F, 5 F per week).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Oncology, Aarhus University Hospital, Aarhus, , Denmark
Department of Oncology, Rigshospitalet, Copenhagen, , Denmark
Department of Oncology, Copenhagen University Hospital at Herlev, Herlev, , Denmark
Department of Oncology, Naestved Hospital, Naestved, , Denmark
Laboratory of Radiation Physics, Odense, , Denmark
Odense University Hospital, Odense, , Denmark
Department of Oncology, Vejle Hospital, Vejle, , Denmark
Contact Details
Name: Olfred Hansen, MD
Affiliation: Odense University Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
